Cite

HARVARD Citation

    Margolin, K. et al. (n.d.). CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma. Journal for immunotherapy of cancer. p. . [Online]. 
  
Back to record